Dr. Oliver Dorigo, MD, PHD
Gynecologic Oncologist
,Reproductive Endocrinologist
,Obstetrician
,Obstetrician / Gynecologist (OBGYN)
Stanford, CA
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Dorigo, Gynecologic Oncologist in Stanford, CA?
Dr. Oliver Dorigo, MD, PHD is a Gynecologic Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified. Dr. Dorigo completed his residency at Ucla Med Ctr/Ucla D Geffen Sch, Obstetrics And Gynecology. Dr. Dorigo is fluent in English, French, German, and Italian, and is currently seeing new patients. Dr. Dorigo’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Dorigo’s office at (650) 723-4000.
Where did Dr. Dorigo go to medical school and complete their residency?
Fellowship: UCLA School of Medicine, Los Angeles, CA | UCLA School of Medicine CA | UCLA
Residency: Ucla Med Ctr/Ucla D Geffen Sch, Obstetrics And Gynecology | UCLA School of Medicine
Medical School: Ruprecht-Karl-Univ- Med Fak- Heidelberg- Germany
Is Dr. Dorigo board certified as a Gynecologic Oncologist?
Yes, Dr. Oliver Dorigo, MD, PHD is board certified by the American Board of Obstetrics and Gynecology , American Board of Obstetrics and Gynecology since 2008, American Board of Obstetrics and Gynecology since 2006
What languages does Dr. Dorigo speak?
Dr. Dorigo and their clinical team can communicate with patients in the following languages:
English
French
German
Italian
What conditions does a Gynecologic Oncologist like Dr. Dorigo typically treat?
As a Gynecologic Oncologist, Dr. Dorigo diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Dorigo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Cancer of the ovary
- Ovarian carcinoma
- Female reproductive cancer
ICD-10 Codes:
- C569: Malignant neoplasm of unspecified ovary
- C562: Malignant neoplasm of left ovary
Also known as:
- Endometrial Cancer
- Uterine Cancer
- Endometrial Cancer Treatment (PDQ®)
- Malignant Endometrial Tumor
- Endometrial Carcinoma
- Cancer of the Endometrium
ICD-10 Codes:
- C541: Malignant neoplasm of endometrium
Also known as:
- Cervical Cancer
- Malignant Cervical Tumor
- Cervical Carcinoma
- Cancer of the Cervix
ICD-10 Codes:
- C539: Malignant neoplasm of cervix uteri, unspecified
Also known as:
- Abdominal or Pelvic Swelling, Mass, or Lump
- Belly lump
- Pelvic mass
- Abdominal swelling
ICD-10 Codes:
- R1900: Intra-abdominal and pelvic swelling, mass and lump, unspecified site
What procedures does a Gynecologic Oncologist like Dr. Dorigo typically perform?
As a Gynecologic Oncologist, Dr. Dorigo performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Dorigo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Laparoscopic Hysterectomy
- Hysterectomy
- Laparoscopy
- Minimally Invasive Hysterectomy
- Keyhole Hysterectomy
- Total Laparoscopic Hysterectomy
- Uterus Removal Surgery
CPT Codes:
- 58571: Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)
Also known as:
- Laparoscopic Ovarian and/or Fallopian Tube Removal
- Laparoscopic Oophorectomy
- Laparoscopic Salpingectomy
- Minimally Invasive Adnexal Removal
CPT Codes:
- 58661: Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)
Also known as:
- Laparoscopic Removal of Pelvic Lesions
- Minimally invasive ovarian lesion removal
- Pelvic lesion excision laparoscopy
- Peritoneal lesion fulguration
- Endometriosis removal surgery
CPT Codes:
- 58662: Laparoscopy, surgical; with fulguration or excision of lesions of the ovary, pelvic viscera, or peritoneal surface by any method
Also known as:
- Hysteroscopy with Biopsy or Polyp Removal
- Biopsy
- Hysteroscopy
- Uterine Scope with Biopsy
- Hysteroscopic Polypectomy
- D&C with Hysteroscopy
CPT Codes:
- 58558: Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or polypectomy, with or without D & C
Also known as:
- Sentinel Lymph Node Mapping
- Lymph Node Identification
- Sentinel Node Biopsy (Mapping)
- Dye Injection for Lymph Nodes
CPT Codes:
- 38900: Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure)
Also known as:
- Retroperitoneal Lymph Node Biopsy (Laparoscopic)
- Laparoscopic Lymph Node Sampling
- Abdominal Lymph Node Biopsy
- Retroperitoneal Biopsy
CPT Codes:
- 38570: Laparoscopy, surgical; with retroperitoneal lymph node sampling (biopsy), single or multiple
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Does Dr. Dorigo accept my insurance?
Dr. Dorigo accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Dorigo accept in Stanford, CA?
Dr. Dorigo in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Centene Corporation
CVS Health (formerly Aetna)
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Dorigo's office located?
Recognitions
Awards
Southern California Super Doctors
OB/GYN Resident Teaching Award,
STOP Cancer Career Development Award, STOP Cancer
Teaching Award, National Council on Resident Education in Obstetrics
Outstanding Podium Presentation Award
National Gynecologic Oncology Fellow's Forum
American Association of Cancer Research Outstanding Poster Award, Tor
Publications
Increased risk and pattern of secondary maligncies in patients with invasive extramammary Paget
, 2014
MMPs in Ovarian Cancer as Therapeutic Targets
, 2012
Correlative nomechanical profiling with super-resolution F
, 2012
Persolizing CA125 Levels for Ovarian Cancer Screening
, 2011
Cisplatin and PI3kise Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells
, 2010
Robust In Vivo Transduction of a Genetically Stable Epstein
, 2009
Dual targeting of mammalian target of rapamycin
, 2009
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
, 2009
Enhanced Expression of L9'S Mutant ChR
, 2006
Development of a novel helper-dependent adenovirus
, 2004
Enhanced expression of L9'S mutant alpha 4 ChR
, 2004
A radical debulking of leiomyomatosis peritonealis dissemita from a colonic obstruction
, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
, 1999
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild
, 1998
Gene therapy for ovarian cancer ? Molecular scissors of the new millenium?
, 1998
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
, 1997
Gene therapy for ovarian cancer: Development of novel treatment strategies
, 1997
Eradication of established intracranial rat gliom
, 1996
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN
, 1995
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNT
, 1993
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
, 1993
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNCIES IN AIDS
, 1993
A MONOCLOL-ANTIBODY
, 1993
NEW TECHNIQUES FOR THE STUDY OF THE CORORY MICROCIRCULATION
, 1992
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS
, 1992
PHARMACOLOGICAL EFFECTS ON CORORY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
, 1990
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
, 1990
Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget
, 2014
Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.
, 2014
MMPs in Ovarian Cancer as Therapeutic Targets
, 2012
Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm
, 2012
Expression of thyroid transcription factor
, 2012
Correlative nanomechanical profiling with super-resolution F
, 2012
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
, 2012
Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma
, 2012
Effect of PI3K/Akt Pathway Inhibition
, 2012
Personalizing CA125 Levels for Ovarian Cancer Screening
, 2011
Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells
, 2010
Robust In Vivo Transduction of a Genetically Stable Epstein
, 2009
Dual targeting of mammalian target of rapamycin
, 2009
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
, 2009
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
, 2008
CA125: Megadaltons of novel opportunities
, 2007
Enhanced Expression of L9'S Mutant nAChR
, 2006
Development of a novel helper-dependent adenovirus
, 2004
Enhanced expression of L9'S mutant alpha 4 nAChR
, 2004
Specific keynote: Immunological therapy for ovarian cancer
, 2003
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
, 2002
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction
, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
, 1999
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild
, 1998
Gene therapy for ovarian cancer ? Molecular scissors of the new millenium?
, 1998
Synergy of transforming growth factor beta
, 1998
Progress and prospects in vaccine therapy for gynecologic cancers.
, 1997
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
, 1997
Gene therapy for ovarian cancer: Development of novel treatment strategies
, 1997
Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine
, 1997
Eradication of established intracranial rat gliom
, 1996
Immuno-gene therapy of colon carcinoma and central nervous tumors
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN
, 1995
INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA
, 1995
CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL
, 1995
INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR
, 1995
Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies
, 1995
VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER
, 1993
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT
, 1993
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
, 1993
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS
, 1993
A MONOCLONAL-ANTIBODY
, 1993
NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION
, 1992
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS
, 1992
PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
, 1990
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
, 1990
What is Dr. Dorigo's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Dorigo's National Provider Identifier (NPI) number is 1306873294.
What common questions do patients ask about Dr. Dorigo?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Dorigo
What is Dr. Oliver Dorigo's specialty?
Dr. Dorigo is a Gynecologic Oncologist near Stanford, CA.
What does a Gynecologic Oncologist do?
An obstetrician/gynecologist specializing in gynecologic oncology provides consultation and comprehensive management for patients with gynecologic cancer. This includes performing diagnostic and therapeutic procedures essential for the total care of patients with gynecologic cancer and addressing any resulting complications.
Is this Dr. Oliver Dorigo affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Dorigo is affiliated with Stanford Health Care - Stanford Hospital, Stanford Health Care - Valleycare, John Muir Health Walnut Creek Medical Center, Novato Community Hospital, Torrance Memorial Medical Center, Mills-Peninsula Medical Center which are a Castle Connolly Top Hospitals. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Gynecologic Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Gynecologic Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Oliver Dorigo accepting new patients in Stanford, CA?
Yes, Dr. Oliver Dorigo is accepting new patients at this time.
Does Dr. Oliver Dorigo offer online booking?
Please contact Dr. Dorigo's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Oliver Dorigo?
Please contact Dr. Dorigo's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Oliver Dorigo have?
Dr. Oliver Dorigo is certified by the American Board of Obstetrics and Gynecology.
Other Gynecologic Oncologist Near Stanford, CA
Gynecologic Oncologist
Accepting patientsGynecologic Oncologist
Accepting patientsGynecologic Oncologist
Accepting patients